Alvotech's AVT05 emerges as leading contender in rheumatoid arthritis market

The patent for Janssen’s second-generation, tumour necrosis factor-alpha (TNF)-a inhibitor Simponi (golimumab), is scheduled to expire in 2024 and in 2025 in the US and EU, respectively.

Related Keywords

Japan ,Australia ,Advanz Pharma ,Momna Ali , ,Rheumatoid Arthritis ,Global Drug Forecast ,Market Analysis ,Bio Developments ,Markets Amp Regulations ,Emerging Markets ,Biosimilars ,Alvotech ,Arthritis ,